Please login to the form below

Not currently logged in
Email:
Password:

kidney disease

This page shows the latest kidney disease news and features for those working in and with pharma, biotech and healthcare.

Ardelyx gets second kidney disease trial win for tenapanor

Ardelyx gets second kidney disease trial win for tenapanor

Drug hit primary and all secondary endpoints. California biotech Ardelyx has a second positive trial for its lead drug tenapanor in chronic kidney disease (CKD), as it waits for an FDA

Latest news

More from news
Approximately 19 fully matching, plus 131 partially matching documents found.

Latest Intelligence

  • 25 Women Leaders in UK Healthcare 25 Women Leaders in UK Healthcare

    The firm has just signed a long-term collaboration with AZ for the discovery of new drugs for chronic kidney disease and idiopathic pulmonary fibrosis (IPF). ... disease and applying machine learning, artificial intelligence and collapsing analysis to

  • Orphan drugs and breakthrough therapies drive Cortellis Drugs to Watch 2019 Orphan drugs and breakthrough therapies drive Cortellis Drugs to Watch 2019

    of JAK proteins is an established method of controlling the symptoms of this disease. ... The sales forecast for Zolgensma is $2.09bn. Roxadustat, from AstraZeneca, FibroGen and Astellas, targets anaemia in chronic kidney disease (CKD).

  • China: AstraZeneca’s new engine for growth and innovation China: AstraZeneca’s new engine for growth and innovation

    FibroGen in China for patients with anaemia in chronic kidney disease. ... AstraZeneca’s goal is to realise complete disease management, covering prevention, screening, diagnosis, treatment and follow- up.

  • The invisible army The invisible army

    Studies with COPD and chronic kidney disease patients indicate that carers can have a positive influence on patient adherence to medication and healthy behaviours, thus driving positive outcomes in the process.

  • Deal Watch December 2016 Deal Watch December 2016

    1, 000. Akebia (US). Otsuka (Japan). Licence (US). Vadadustat: oral hypoxia-inducible factor (HIF) stabiliser in phase III for anaemia of chronic kidney disease. ... inflammatory bowel disease and multiple sclerosis.

More from intelligence
Approximately 0 fully matching, plus 18 partially matching documents found.

Latest appointments

More from appointments
Approximately 0 fully matching, plus 2 partially matching documents found.

Latest from PMHub

  • Its Know Your Numbers week

    One in 4 adults in the UK has high blood pressure so the risk of developing heart disease, heart attacks, strokes, kidney disease and vascular dementia are very real. ... Lack of exercise. Being overweight. Chronic Kidney Disease. Regularly drinking

  • What are you doing, Dave?

    parents. Google's DeepMind is exploring the use of AI in managing head and neck cancer, acute kidney injury, and detection of eye disease. ... The IBM Watson supercomputer is also being used to help manage cancer, as well as analysing data on genes,

  • Lighthouse Medical Communications US makes the list of finalists for the 2018 PM360 Trailblalzer Awards

    This exciting news is a true testament to the American Kidney Fund’s commitment to improving the lives of patients with chronic kidney disease.  ACT on Anemia was one of a ... ACT on Anemia - Anemia in Chronic Kidney Disease, is a multi-channel

  • Making good practice common practice in rare disease

    However, fatigue scores can’t be explained purely by disease activity and depression. ... 2015 - 88% of people with early-stage autosomal dominant polycystic kidney disease (ADPKD), reported physical symptoms including pain and general malaise.

More from PMHub
Approximately 0 fully matching, plus 4 partially matching documents found.

Featured jobs

Subscribe to our email news alerts

PMHub

Add my company
mXm Medical Communications

mXm Medical Communications meets the needs of pharmaceutical marketers and medics who require a highly experienced, bespoke service from their...

Latest intelligence

Report: Customer experience, shaping digital healthcare
In this issue of ‘Perspective’ we speak with industry experts to learn about the world of digital healthcare, and how pharma is beginning to utilise these modern technologies to enhance...
Biomarker
Encouraging signs in biomarker R&D
The cancer immunotherapy firms ramping-up biomarker R&D...
Programmatic methodology and why you should be using it
What is it? How does it work? Why is everyone talking about it? By Richard Webb - Associate Director...

Infographics